Adjuvant Holdings Co (TSE:4929) Research & Development: 円0 Mil (TTM As of Mar. 2026)


TSE:4929 Adjuvant Holdings Co Ltd TSE:4929
66 GF Score
Price 円717.00
GF Value 円736.83
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Adjuvant Holdings Co Research & Development?

Adjuvant Holdings Co TSE:4929 66 Research & Development is 円0 Mil as of Mar. 2026. GuruFocus rates TSE:4929 with a GF Score™ of 66/100 and a GF Value™ of 円736.83 (Fairly Valued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Adjuvant Holdings Co's Research & Development for the six months ended in Mar. 2026 was 円0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was 円0 Mil.

Adjuvant Holdings Co  (TSE:4929) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Adjuvant Holdings Co Research & Development Related Terms

Adjuvant Holdings Co Research & Development Historical Data

* Premium members only.

The historical data trend for Adjuvant Holdings Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adjuvant Holdings Co Research & Development Chart

Adjuvant Holdings Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Adjuvant Holdings Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4929
66GF Score
Adjuvant Holdings Co Ltd TSE:4929
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adjuvant Holdings Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円0 Mil mean?
Adjuvant Holdings Co (TSE:4929) has a Research & Development of 円0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Adjuvant Holdings Co and its competitors.
Is Adjuvant Holdings Co's Research & Development too high?
Adjuvant Holdings Co's current Research & Development is 円0 Mil. Overall, Adjuvant Holdings Co has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Adjuvant Holdings Co's Research & Development compare to PG and CL?
Adjuvant Holdings Co's Research & Development of 円0 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Consumer Packaged Goods company?
A good Research & Development depends on the Consumer Packaged Goods industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Adjuvant Holdings Co and its competitors. Adjuvant Holdings Co's current Research & Development is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adjuvant Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Adjuvant Holdings Co (TSE:4929) is currently considered Fairly Valued. The stock's GF Value™ is 円736.83, compared to a current price of 円717.00 — trading 2.7% below its estimated fair value. The current Research & Development is 円0 Mil. Adjuvant Holdings Co's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Adjuvant Holdings Co (TSE:4929), the current Research & Development is 円0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adjuvant Holdings Co (TSE:4929) Overvalued in 2026?

Based on GuruFocus' analysis, Adjuvant Holdings Co stock appears to be undervalued. The current stock price of 円717.00 is trading 2.7% below its estimated GF Value™ of 円736.83. GuruFocus considers Adjuvant Holdings Co to be Fairly Valued.

Key valuation signals for TSE:4929:

  • Research & Development: 円0 Mil
  • GF Value™: 円736.83 vs. price of 円717.00 (2.7% below fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the TSE:4929 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adjuvant Holdings Co Business Description

Address 5-5-5 Shimoyamatedori, Chuo-ku, Hyogo Prefecture, Kobe City, JPN, 650-0011
Adjuvant Holdings Co Ltd, formerly Adjuvant Cosme Japan Co Ltd is engaged in the research, development, production, and sale of cosmetics in Japan. It offers skin care products, including cleansing products, facial cleansers, lotions, beauty essences, masks, moisturizing creams, makeup bases, makeup, and body care products among other products.
66GF Score

Get the complete analysis for TSE:4929

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円717.00
Price
円736.83
GF Value